Welcome to our dedicated page for Theravance Bioph news (Ticker: TBPH), a resource for investors and traders seeking the latest updates and insights on Theravance Bioph stock.
Theravance Biopharma, Inc. reports biopharmaceutical developments centered on YUPELRI® (revefenacin) inhalation solution, an FDA-approved maintenance treatment for chronic obstructive pulmonary disease. Company updates commonly address YUPELRI collaboration revenue, U.S. net sales recognized by Viatris, hospital-channel demand, brand profitability, and intellectual-property matters related to generic challenges.
Theravance news also covers portfolio changes following the Phase 3 CYPRESS study of ampreloxetine in symptomatic neurogenic orthostatic hypotension due to multiple system atrophy, including the decision to wind down that program. Recurring corporate updates include cost-reduction actions, operating expense trends, TRELEGY milestone economics reported by GSK, cash position, and governance or capital-allocation reviews.
Theravance Biopharma (NASDAQ: TBPH) will report its third quarter 2025 financial results and provide a business update after market close on Monday, November 10, 2025. A conference call and simultaneous webcast are scheduled for 5:00 PM ET (2:00 PM PT / 10:00 PM GMT) that day.
Investors may join the live call by telephone with pre-registration or listen via the live audio webcast on the company’s Investors Events and Presentation page. A replay of the webcast will be available on the company website through December 10, 2025.
Theravance Biopharma (NASDAQ: TBPH) will report its third quarter 2025 financial results and provide a business update after market close on Monday, November 10, 2025. A conference call and simultaneous webcast are scheduled for 5:00 PM ET (2:00 PM PT / 10:00 PM GMT) that day.
Investors may join the live call by telephone with pre-registration or listen via the live audio webcast on the company’s Investors Events and Presentation page. A replay of the webcast will be available on the company website through December 10, 2025.
Theravance Biopharma (NASDAQ: TBPH) launched “Power in the Periphery,” a disease education campaign for healthcare professionals to raise awareness of neurogenic orthostatic hypotension (nOH) in Multiple System Atrophy (MSA).
The initiative was introduced at the International Congress of Parkinson’s Disease and Movement Disorders (MDS) in Honolulu, October 5–9, 2025, and aims to deepen scientific understanding of nOH pathophysiology in MSA and improve clinician engagement. nOH symptoms include lightheadedness, fainting, fatigue, blurry vision, weakness, concentration problems, and head/neck pain. Theravance directs clinicians to www.nOHUncovered.com for educational resources.
Theravance Biopharma (NASDAQ: TBPH) will present two rapid-fire analyses of YUPELRI (revefenacin) at the 2025 CHEST Annual Meeting in Chicago, Oct 19–22, 2025.
A retrospective claims study reported that patients adherent to YUPELRI after COPD hospital discharge had significantly fewer and less severe exacerbations and significantly lower healthcare costs versus non-adherent patients. Post-hoc analyses of a 52-week Phase 3 safety study found lower incidence of moderate-to-severe exacerbations and overall less severe exacerbations versus tiotropium. Presentation details list presenters, titles, and Oct 21, 2025 times.
Theravance Biopharma (NASDAQ: TBPH) will present two rapid-fire analyses of YUPELRI (revefenacin) at the 2025 CHEST Annual Meeting in Chicago, Oct 19–22, 2025.
A retrospective claims study reported that patients adherent to YUPELRI after COPD hospital discharge had significantly fewer and less severe exacerbations and significantly lower healthcare costs versus non-adherent patients. Post-hoc analyses of a 52-week Phase 3 safety study found lower incidence of moderate-to-severe exacerbations and overall less severe exacerbations versus tiotropium. Presentation details list presenters, titles, and Oct 21, 2025 times.
Theravance Biopharma (NASDAQ: TBPH) announced its participation in the upcoming H.C. Wainwright 27th Annual Global Investment Conference in New York City. CEO Rick Winningham will engage in a Fireside Chat on September 9, 2025, at 1:30 PM EDT.
The company will offer in-person meeting opportunities for interested investors through H.C. Wainwright representatives. A live webcast will be available online, with a replay accessible on Theravance's website for 30 days following the event.
Theravance Biopharma (NASDAQ: TBPH) has completed enrollment in its pivotal Phase 3 CYPRESS study of ampreloxetine for treating symptomatic neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA). The study targets an underserved population of approximately 40,000 U.S. patients.
The CYPRESS trial is a global, randomized-withdrawal study with a 12-week open-label portion followed by an 8-week randomized phase. The company expects topline results in Q1 2026 and plans to pursue an expedited NDA submission with potential priority FDA review. Ampreloxetine has received Orphan Drug Designation in the U.S., highlighting the significant unmet need in treating nOH due to MSA.
Theravance Biopharma (NASDAQ:TBPH) reported strong Q2 2025 financial results, highlighted by YUPELRI® net sales of $66.3 million, representing a 22% year-over-year increase. The company completed a significant transaction, selling its TRELEGY ELLIPTA royalty interest to GSK for $225 million.
Key financial metrics include total revenue of $26.2 million and a net income of $54.8 million. The company maintains a robust balance sheet with $338.8 million in cash and no debt. The pivotal Phase 3 CYPRESS study for ampreloxetine is expected to complete enrollment by late summer, with top-line data anticipated six months later.
TRELEGY's year-to-date performance puts it on track to trigger a $50 million milestone payment in 2025, with Q2 2025 global net sales reaching approximately $1.1 billion.
Theravance Biopharma (NASDAQ: TBPH) has scheduled its second quarter 2025 financial results announcement and business update for August 12, 2025, after market close. The company will host a conference call and webcast at 5:00 pm ET on the same day.
Interested participants can pre-register for the telephone conference, while those preferring to listen via the internet can access the webcast through the company's website. A replay will be available for 30 days through September 11, 2025.
Theravance Biopharma (NASDAQ: TBPH) announced its participation in the upcoming BTIG Virtual Biotechnology Conference. The company will engage in a fireside chat on Wednesday, July 30 at 12:00 pm ET (9:00 am PT/5:00 pm IST). Senior management will also be available for one-on-one meetings with investors during the conference.
Interested parties can access the webcast or schedule meetings through their BTIG representative or by emailing uscorporateaccess@btig.com.